Aligos is selling shares, pre-funded warrants and warrants at $26.0825 per share and warrant to fund a Phase 2 study of ALG-000184 and extend cash into the second half of 2026.
Latest Aligos Therapeutics news
We have not published a story on Aligos Therapeutics yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $30.4 million, plus short-term investments of $0, $30.4 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Aligos Therapeutics
Has Aligos Therapeutics raised money recently?
Our latest story on this, dated Feb 12, 2025: "Aligos Therapeutics announces $105 million private placement". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Aligos Therapeutics?
Aligos Therapeutics, Inc. trades under the ticker ALGS on NASDAQ.
Where is Aligos Therapeutics listed?
Aligos Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:5WK0; LS:A40LQ4.
What is the SEC CIK of Aligos Therapeutics?
The SEC Central Index Key (CIK) for Aligos Therapeutics, Inc. is 1799448. Its filings are on SEC EDGAR.
How many shares does Aligos Therapeutics have outstanding?
42,608,792 shares as of 2021-08-04, per the cover page of its 10-Q filed 2021-08-05.
Which country or territory is Aligos Therapeutics listed under?
Our directory records Aligos Therapeutics, Inc. under United States.
What does Aligos Therapeutics do?
Our directory classifies Aligos Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Aligos Therapeutics?
The ISIN recorded for Aligos Therapeutics, Inc. is US01626L2043.
Does aibio.space cover Aligos Therapeutics?
aibio.space lists Aligos Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Aligos Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What was Aligos Therapeutics's revenue last year?
$2.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Aligos Therapeutics profitable?
Aligos Therapeutics, Inc. reported a net loss of $24.2 million for the fiscal year ended Dec 31, 2025, and used $82.5 million of cash in operations, per its annual report to the SEC.
How much does Aligos Therapeutics spend on research and development?
$69.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Aligos Therapeutics have?
$30.4 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Aligos Therapeutics (ALGS) stock news?
Our latest story on Aligos Therapeutics, dated Feb 12, 2025: "Aligos Therapeutics announces $105 million private placement". Aligos is selling shares, pre-funded warrants and warrants at $26.0825 per share and warrant to fund a Phase 2 study of ALG-000184 and extend cash into the second half of 2026. Source.
Investor discussion: Aligos Therapeutics
Members talk about Aligos Therapeutics (ALGS). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Aligos Therapeutics, newest first. Each line links the filing it comes from.
Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). Source
Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:ALGS on TradingView.
SEC filings and registration
SEC name
Aligos Therapeutics, Inc.
CIK
1799448
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
ALGS (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
Phone
(800) 466-6059
Shares outstanding
42,608,792 as of 2021-08-04 (10-Q filed 2021-08-05)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Aligos Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ALGS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio